Skip to main content
SpringerLink
Log in

Immune Modulation Therapy — Peripheral Vascular Disease — Vasogen

(VasoCare™)

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Notes

  1. 1This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.

References

  1. Vasogen announces initial results from Raynaud’s trial. Business Wire [online]: [3 pages], 10 Sep 1997. Available from URL: http://www.newspage.com

    Google Scholar 

  2. Vasogen Inc. Vasogen announces positive results from VasoCare⊥M clinical trial in peripheral vascular disease. Media Release: [4 pages], 29 Nov 2000. Available from URL:http://www.vasogen.com

    Google Scholar 

  3. Vasogen Inc. Study confirms Vasogen therapy’s ability to improve blood vessel function in atherosclerosis. Media Release: [2 pages], 7 Jun 2000. Available from URL: http://www.vasogen.com

    Google Scholar 

  4. Vasogen reports results of St. Bartholomew’s study. Business Wire [online]: [2 pages], 25 Feb 1997. Available from URL: http://www.newspage.com

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Immune Modulation Therapy — Peripheral Vascular Disease — Vasogen. Drugs R&D 3, 358–360 (2002). https://doi.org/10.2165/00126839-200203050-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200203050-00013

Keywords

Search

Navigation